This inventor holds 6 USPTO granted patents and 3 published patent applications and 2 EPO patents. Top assignees: Athenex Hk Innovative Limited, Atnx Spv, LLC, Athenex, Inc.. Active years: 2020-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
3 out of 7 
2 out of 3 
1 out of 13 
Years Active: 2020-2026
Title: The Innovative Contributions of E Douglas Kramer in Cancer Treatment
Introduction
E Douglas Kramer, an accomplished inventor based in Stamford, CT, has made significant strides in the field of pharmaceutical innovations. With a portfolio of five patents, his work primarily focuses on enhancing cancer treatment methodologies and improving patient outcomes.
Latest Patents
Among his notable contributions, two of Kramer's latest patents stand out. The first is a groundbreaking therapeutic combination of orally administered irinotecan and a P-glycoprotein (P-gp) inhibitor, aimed at treating cancer effectively. This innovative combination seeks to reduce or prevent toxicity and hypersensitivity-type infusion reactions linked to intravenously administered irinotecan therapy in cancer patients. The second patent addresses methods for treating and preventing actinic keratosis, wherein Kramer's formulation involves administering a therapeutically effective amount of KX-01 to individuals in need of such treatment.
Career Highlights
Kramer's illustrious career has seen him work with prominent companies in the pharmaceutical sector, including Athenex Hk Innovative Limited and Athenex, Inc. His expertise in the development of innovative treatment combinations and methodologies has positioned him as a key figure in the fight against cancer.
Collaborations
Throughout his career, E Douglas Kramer has enjoyed fruitful collaborations with esteemed colleagues, including Min-Fun Rudolf Kwan and Johnson Yiu-Nam Lau. These partnerships have strengthened his research efforts, leading to the advancement of therapeutic solutions that hold promise for patients battling cancer and related conditions.
Conclusion
In conclusion, E Douglas Kramer's contributions to pharmaceutical innovation, particularly in cancer treatment, underscore the importance of addressing patient needs through scientific advancements. His work exemplifies the spirit of innovation and showcases the impact that dedicated inventors can have on improving healthcare outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile